Chimeric antigen receptor (CAR) T cells have changed the treatment landscape of relapsed
or refractory diffuse large B cell lymphoma. This review focuses on the biology of …

Overall, around 40% of patients with diffuse large B-cell lymphoma (DLBCL) have refractory
disease or relapse after the first line of treatment. Until relatively recently, the prognosis of …

The combination of carmustine, etoposide, cytarabine, and melphalan (BEAM) as
conditioning regimen prior to autologous stem-cell transplantation (ASCT) remains the …

High-risk relapsed or refractory (R/R) classical Hodgkin lymphoma (HL) is associated with
poor outcomes after conventional salvage therapy and autologous hematopoietic cell …

With the advent of new cellular and targeted therapies, treatment options for relapsed and
refractory (r/R) lymphomas have multiplied, and the optimal approach offering the best …

The prognosis for patients with CD30+ lymphomas (Hodgkin lymphoma and various T-cell
lymphomas) relapsing after autologous stem cell transplantation (ASCT) is critical …

Purpose High-dose chemotherapy followed by autologous stem cell transplantation (ASCT)
is the standard management for relapsed or high-risk non-Hodgkin's lymphoma (NHL). We …

目的: 探讨含苯达莫司汀的移植预处理方案[BeEAM (苯达莫司汀+ 依托泊苷+ 阿糖胞苷+ 马法兰)
和BeEAC (苯达莫司汀+ 依托泊苷+ 阿糖胞苷+ 环磷酰胺)] 在淋巴瘤自体造血干细胞移植(ASCT) …

The remarkable evolution of hematopoietic stem cell transplant (HSCT) over the years
driven by the advances in donor selection, conditioning regimen, supportive care, GVHD …

Autologous stem cell transplant (ASCT) is an effective treatment for non-Hodgkin lymphoma
(NHL). However, recent supply issues and toxicity of carmustine have necessitated a new …